Microchip Technology
MCHP
$84.69
+13.89%
Microchip Technology Inc. is a leading semiconductor company that designs and manufactures microcontrollers (MCUs), analog devices, and other embedded control products used in a vast array of electronic applications, from automotive systems and industrial equipment to consumer electronics and IoT devices. The company holds a dominant position in the 8-bit MCU market, leveraging its broad portfolio and design-in ecosystem to serve a diverse customer base, and has expanded into higher-end MCUs and analog chips to strengthen its competitive moat. Currently, the stock is under the spotlight as it navigates a cyclical recovery in the semiconductor industry, with recent quarterly results showing a strong rebound in revenue and profitability after a prolonged downturn, while investors debate the sustainability of this recovery and the company's ability to manage its elevated debt load and capital returns in a rising-rate environment.…
MCHP
Microchip Technology
$84.69
Related headlines
Investment Opinion: Should I buy MCHP Today?
Based on the analysis, MCHP is rated a Buy. The thesis is that the company is in the early stages of a cyclical recovery, with strong revenue growth and margin expansion, and the stock is undervalued relative to its forward earnings potential. The analyst consensus is 'Buy' with an average target of $113.08, implying 52% upside from the current price of $74.36.
Sign up to view all
MCHP 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The strong revenue recovery, margin expansion, and attractive forward valuation support a positive outlook. However, the elevated debt and high beta introduce uncertainty. The stock is likely to outperform if the recovery continues, but investors should monitor the company's ability to sustain growth and manage debt. An upgrade to high confidence would occur if revenue growth accelerates and debt levels decline, while a downgrade would be warranted if the recovery stalls or margins compress.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Microchip Technology's 12-month outlook, with a consensus price target around $109.21 and implied upside of +28.9% versus the current price.
Average Target
$109.21
0 analysts
Implied Upside
+28.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$80 - $135
Analyst target range
Microchip is covered by 24 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.56 (where 1 is Strong Buy and 5 is Sell), indicating a bullish stance. The average target price is $113.08, implying approximately 52% upside from the current price of $74.36, which reflects strong conviction in the company's recovery. The target price range spans from a low of $80.00 to a high of $135.00, with the low target still representing a 7.6% upside, suggesting that even the most bearish analyst sees limited downside. Recent ratings actions have been predominantly neutral to positive, with firms like TD Cowen maintaining a Hold, while Cantor Fitzgerald, UBS, JP Morgan, Needham, and Evercore ISI all maintain Overweight or Buy ratings, indicating a stable and optimistic outlook. The wide spread between the low and high targets (55% difference) highlights the uncertainty around the pace of the cyclical recovery and the company's ability to sustain margin expansion, but the overall consensus points to a favorable risk-reward profile for investors willing to tolerate near-term volatility.
Drowning in data?
Find the real signal!
Bulls vs Bears: MCHP Investment Factors
Microchip is in the early stages of a cyclical recovery, with strong revenue growth, margin expansion, and a bullish analyst consensus. However, the elevated debt load, high trailing PE, and weak relative strength present significant risks. The bull case is supported by the forward PE discount and 52% upside to analyst targets, while the bear case hinges on the sustainability of the recovery and potential margin compression. The most critical tension is whether the earnings recovery can continue at a pace that justifies the forward valuation, or if cyclical headwinds will stall the momentum. Currently, the evidence slightly favors the bulls, but the stock's high beta and recent underperformance warrant caution.
Bullish
- Strong Revenue Recovery: Q4 FY2026 revenue surged 35.1% YoY to $1.311 billion, with sequential growth from $1.186 billion in Q3, indicating a robust cyclical upswing. This marks a clear inflection from the trough of $970.5 million in Q4 FY2025.
- Margin Expansion: Gross margin improved to 60.98% in Q4 FY2026 from 51.6% a year earlier, and operating margin swung from -10.3% to 16.1%. This demonstrates strong pricing power and cost control as volumes recover.
- Analyst Consensus Buy: With 24 analysts, the consensus is 'Buy' with a mean score of 1.56 (1=Strong Buy) and an average target of $113.08, implying ~52% upside from the current price of $74.36. Even the low target of $80 offers 7.6% upside.
- Attractive Forward Valuation: Forward PE of 17.7x is a 19.5% discount to the semiconductor industry average of ~22x, and sits near the lower end of its historical range (15.4x to 200x). This suggests the market is not pricing in a full recovery.
Bearish
- Elevated Debt Levels: Debt-to-equity ratio of 0.86 is high, and interest expense of $51.7 million in Q4 FY2026 (up from $67.9M in Q4 FY2025) consumes a significant portion of operating income. Rising rates could pressure earnings.
- High Trailing PE Distortion: Trailing PE of 239.3x is distorted by the recent trough in earnings (EPS of $0.0058 TTM). This makes the stock appear expensive on a trailing basis, and any earnings miss could trigger a sharp de-rating.
- Cyclicality and End-Market Concentration: Revenue is heavily dependent on automotive and industrial markets, which are cyclical. A slowdown in these sectors could reverse the recovery, as seen in the -34.9% max drawdown from the 52-week high.
- Weak Relative Strength: The stock has underperformed the S&P 500 over the past 1, 3, and 6 months, with relative strength of -9.1%, -29.1%, and -13.5% respectively. This suggests persistent selling pressure and negative momentum.
MCHP Technical Analysis
Microchip's stock has exhibited a volatile, range-bound pattern over the past year, with a 1-year price change of +12.4% but a significant drawdown of -34.9% from its 52-week high. As of August 6, 2026, the stock trades at $74.36, which is approximately 70% of its 52-week range (low of $48.52, high of $105.91), indicating it is closer to the lower end after a sharp pullback. This positioning suggests the stock is in a corrective phase after a strong rally, potentially offering a value opportunity if the underlying fundamentals support a rebound, but also carrying the risk of further downside if the downtrend persists.
Beta
1.74
1.74x market volatility
Max Drawdown
-34.9%
Largest decline past year
52-Week Range
$49-$106
Price range past year
Annual Return
+27.9%
Cumulative gain past year
| Period | MCHP Return | S&P 500 |
|---|---|---|
| 1m | -0.9% | +2.4% |
| 3m | -14.5% | +4.6% |
| 6m | +11.4% | +11.7% |
| 1y | +27.9% | +21.4% |
| ytd | +30.2% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MCHP Fundamental Analysis
Microchip's revenue has shown a strong recovery, with the most recent quarter (Q4 FY2026, ended March 31, 2026) reporting revenue of $1.311 billion, a 35.1% year-over-year increase, and a sequential acceleration from the prior quarter's $1.186 billion. This marks a clear inflection from the trough in Q4 FY2025 when revenue was $970.5 million, and the multi-quarter trend shows consistent growth from $1.076 billion in Q1 FY2026 to $1.311 billion in Q4, indicating a robust cyclical upswing. The growth is broad-based, with semiconductor products contributing $1.272 billion and technology licensing adding $39.5 million, though the company's reliance on the automotive and industrial end markets remains a key driver. The company returned to profitability, with net income of $144.2 million in Q4 FY2026, a dramatic improvement from the net loss of $154.6 million in the year-ago quarter, and gross margin expanded to 60.98% from 51.6% a year earlier, reflecting improved pricing and cost controls. Operating margin also improved to 16.1% from -10.3% in Q4 FY2025, though it remains below the company's historical highs of over 30% seen in 2022-2023, indicating room for further margin recovery as the cycle matures. Microchip's balance sheet shows a debt-to-equity ratio of 0.86, which is elevated but manageable, and the company generated free cash flow of $242.8 million in Q4 FY2026, contributing to a trailing twelve-month FCF of $871 million. The current ratio of 2.09 indicates ample liquidity, and the company's ROE of 3.14% and ROA of 2.23% are recovering from negative levels but remain below historical averages, reflecting the lingering impact of the downturn and the company's high debt load.
Quarterly Revenue
$1.3B
2026-03
Revenue YoY Growth
+35.1%
YoY Comparison
Gross Margin
61.0%
Latest Quarter
Free Cash Flow
$871000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MCHP Overvalued?
Given that Microchip's trailing twelve-month net income is positive (EPS of $0.0058), the PE ratio is the primary valuation metric, but the trailing PE of 239.3x is distorted by the recent trough in earnings, making the forward PE of 17.7x a more meaningful gauge of value. The wide gap between trailing and forward PE implies the market expects a significant earnings recovery, which is consistent with the recent quarterly results and analyst estimates for EPS of $4.57 in the next fiscal year. Compared to the semiconductor industry average PE of approximately 22x (based on available data), Microchip's forward PE of 17.7x represents a 19.5% discount, which may be justified by its lower growth prospects relative to high-flying AI-focused peers, but also reflects the market's skepticism about the durability of its recovery. Historically, Microchip's PE has ranged from as low as 15.4x in 2022 to over 200x during the downturn, and the current forward PE sits near the lower end of its historical band, suggesting the stock is not overvalued on a forward basis, though the elevated debt and cyclicality warrant caution.
PE
239.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 15x~134x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
28.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are prominent: Microchip's debt-to-equity ratio of 0.86 is elevated, and interest expense of $51.7 million in Q4 FY2026 (though down from $67.9M a year ago) still consumes a significant portion of operating income. The company's return on equity of 3.14% and return on assets of 2.23% are recovering but remain low, reflecting the lingering impact of the downturn. Additionally, the trailing PE of 239.3x is distorted by the recent trough in earnings, making the stock vulnerable to any earnings disappointment. The company's reliance on cyclical end markets (automotive, industrial) adds to earnings volatility, as evidenced by the swing from a net loss of $154.6 million in Q4 FY2025 to a profit of $144.2 million in Q4 FY2026.
FAQ
The key risks are: (1) Financial risk from the elevated debt-to-equity ratio of 0.86, which could strain earnings if interest rates rise; (2) Cyclical risk from dependence on automotive and industrial markets, which could reverse the recovery; (3) Market risk from the high beta of 1.742, which amplifies market downturns; (4) Competitive risk from larger peers like Texas Instruments. The most severe risk is a cyclical downturn, which could lead to a 35% drop to the 52-week low of $48.52.
The 12-month forecast is bullish, with a base case target of $90-$113 (50% probability), a bull case target of $100-$135 (30% probability), and a bear case target of $48-$80 (20% probability). The most likely scenario is the base case, where the recovery continues at a moderate pace, driving the stock to the analyst average target of $113.08. The key assumption is that revenue growth remains above 25% YoY and gross margins stay above 58%.
On a forward basis, MCHP is undervalued, with a forward PE of 17.7x versus the industry average of ~22x, a 19.5% discount. However, the trailing PE of 239.3x is distorted by the recent earnings trough, making the stock appear overvalued on a trailing basis. The PS ratio of 7.4x is also above the industry average, but this is typical for a company in a recovery phase. Overall, the market is pricing in a significant earnings recovery, and if that recovery materializes, the stock is undervalued; if not, it could be overvalued.
MCHP is a good buy for investors with a medium-to-high risk tolerance, given the 52% upside to the average analyst target of $113.08. The forward PE of 17.7x is a 19.5% discount to the industry average, and the company is showing strong revenue recovery and margin expansion. However, the high beta of 1.742 and elevated debt levels mean the stock is volatile and could suffer significant losses in a downturn. It is a good buy for those who believe the cyclical recovery will continue and are willing to hold through volatility.
MCHP is more suitable for long-term investment, given its cyclical nature and high beta of 1.742. Short-term trading is risky due to the stock's volatility, as seen in the 1-month price change of -11.6%. For long-term investors, the company's strong position in the MCU market and potential for earnings growth make it a viable holding over a 3-5 year period. The dividend yield of 3.12% provides some income while waiting for the recovery to play out. A minimum holding period of 2-3 years is recommended to ride out the cyclical volatility.
